top menu action banner

GEFINIX (GEFITINIB) 250MG 30`S

Ksh 10,649

In Stock

  • Product Categories:

What is this medicine for?

GEFINIX is a targeted cancer therapy for a specific type of lung cancer. It works by blocking a faulty protein (EGFR — epidermal growth factor receptor) that drives cancer cell growth when there is a particular genetic change (mutation) in the tumour. By blocking this signal, it stops the cancer cells from growing and dividing.

It is mainly used for management of metastatic non-small cell lung cancer with EGFR exon 19 deletions or exon 21 substitution mutations.

 

⚠️ GENETIC TEST REQUIRED FIRST

GEFINIX only works if your lung cancer has a specific EGFR mutation (exon 19 deletion or L858R). Your oncologist must test your tumour (from a biopsy or a blood test) for this mutation before prescribing. Without this mutation, gefitinib is unlikely to work.

 

How do I take it?

       Take ONE tablet (250 mg) once a day

       Can be taken at any time of day — with or without food

       Swallow whole with water

       If you cannot swallow tablets, dissolve the tablet in half a glass of still water, stir well, and drink immediately. Rinse the glass and drink the rinse too.

       If you miss a dose and your next dose is more than 12 hours away, take the missed dose. If it is less than 12 hours to your next dose, skip the missed one.

 

What side effects might I notice?

Very common:

       Skin rash — acne-like spots, particularly on the face, chest, and back (affects 5–7 in 10 patients). Paradoxically, a rash often means the medicine is working.

       Diarrhoea — manage with diet (bland foods, plenty of fluids); contact your team if severe

       Dry skin, brittle nails, or nail fold infections (paronychia)

       Elevated liver enzymes (detected on blood tests — usually no symptoms)

       Reduced appetite, mouth sores, mild nausea

 

🚨 STOP IMMEDIATELY AND GO TO HOSPITAL IF

You develop new or worsening breathlessness, a dry cough, or fever — these could be signs of interstitial lung disease (ILD), a rare but potentially life-threatening side effect. Do not wait for your next appointment. An urgent CT scan will be needed.

 

Important monitoring during treatment

       Liver function blood tests: monthly for the first 3 months, then every 3 months

       CT chest scan: at 8–12 weeks to assess response, then every 3 months

       INR check if you are on warfarin: more frequent monitoring needed

 

Who should NOT take this medicine?

       Pregnant women or those planning to become pregnant — gefitinib can harm an unborn baby

       Breastfeeding women

       Anyone allergic to gefitinib

       Patients with severe liver disease

Use effective contraception during treatment and for at least 1 month after the last dose.

 

What happens if the medicine stops working?

Most patients respond well for 9–14 months before the cancer develops resistance. When this happens, your oncologist will arrange a repeat biopsy or blood test to identify the type of resistance. The most common resistance change (T790M mutation) can be treated with a different, newer medicine. Your oncologist will guide the next steps.

 

Frequently Asked Questions

Do I need a genetic test before starting GEFINIX?

Yes — gefitinib only works in patients whose tumour has certain EGFR mutations. Without the right mutation, you could be taking a medicine that will not work for your type of lung cancer. The test is done on a tumour biopsy or a blood test (liquid biopsy). Your oncologist will arrange this before prescribing.

What should I do if I develop breathlessness while taking GEFINIX?

Stop taking GEFINIX immediately and go to the hospital or contact your oncologist the same day. New breathlessness, dry cough, or fever could be a sign of interstitial lung disease (ILD) — a rare but potentially life-threatening lung inflammation. An urgent CT chest scan will be needed. Gefitinib is permanently stopped if ILD is confirmed.

What is the difference between GEFINIX (gefitinib) and other similar medicines?

Gefitinib was the first targeted EGFR medicine for lung cancer. Erlotinib is very similar but must be taken on an empty stomach. Osimertinib (Tagrisso) is a newer, third-generation option that is often preferred where available, as it works better in the brain and lasts longer. Your oncologist will recommend the best option based on your situation, test results, and access.


 

Customer Feedback


Recently Viewed